16. Wallace DB, Ellis CE, Espach A, Smith SJ, Greyling RR, et al. (2006) Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever. Vaccine 24: 7181–7189. 17. Jansen van Vuren P, Tiemessen CT, Paweska JT (2010) Evaluation of a recombinant Rift Valley fever virus subunit nucleocapsid protein as an immunogen in mice and sheep. The Open Vaccine Journal 3: 114–126. 18. Heise MT, Whitmore A, Thompson J, Parsons M, Grobbelaar AA, et al. (2009) An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus. Epidemiol Infect 137: 1309–1318. 19. Kortekaas J, de Boer SM, Kant J, Vloet RP, Antonis AF, et al. (2010) Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector. Vaccine 28: 4394–4401. 20. Mandell RB, Koukuntla R, Mogler LJ, Carzoli AK, Freiberg AN, et al. (2010) A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge. Virology 397: 187–198. 21. Morrill JC, Jennings GB, Johnson AJ, Cosgriff TM, Gibbs PH, et al. (1990) Pathogenesis of Rift Valley fever in rhesus monkeys: role of interferon response. Arch Virol 110: 195–212. 22. Sandrock M, Frese M, Haller O, Kochs G (2001) Interferon-induced rat Mx proteins confer resistance to Rift Valley fever virus and other arthropod-borne viruses. J Interferon Cytokine Res 21: 663–668. 23. Anderson GW, Jr., Peters CJ (1988) Viral determinants of virulence for Rift Valley fever (RVF) in rats. Microb Pathog 5: 241–250. 24. Peters CJ, Jones D, Trotter R, Donaldson J, White J, et al. (1988) Experimental Rift Valley fever in rhesus macaques. Arch Virol 99: 31–44. 25. Le May N, Mansuroglu Z, Leger P, Josse T, Blot G, et al. (2008) A SAP30 complex inhibits IFN-beta expression in Rift Valley fever virus infected cells. PLoS Pathog 4: e13. 26. Bouloy M, Weber F (2010) Molecular biology of rift valley Fever virus. Open Virol J 4: 8–14. 27. Le May N, Dubaele S, Proietti De Santis L, Billecocq A, Bouloy M, et al. (2004) TFIIH transcription factor, a target for the Rift Valley hemorrhagic fever virus. Cell 116: 541–550. 28. Habjan M, Pichlmair A, Elliott RM, Overby AK, Glatter T, et al. (2009) NSs protein of rift valley fever virus induces the specific degradation of the double- stranded RNA-dependent protein kinase. J Virol 83: 4365–4375. 29. Strauss JH, Strauss EG (2008) Viruses and Human Disease, 2nd Edition. Oxford: Elsevier. pp 468. 30. Morrill JC, Czarniecki CW, Peters CJ (1991) Recombinant human interferon- gamma modulates Rift Valley fever virus infection in the rhesus monkey. J Interferon Res 11: 297–304. 31. Bouloy M, Janzen C, Vialat P, Khun H, Pavlovic J, et al. (2001) Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs. J Virol 75: 1371–1377. 32. Won S, Ikegami T, Peters CJ, Makino S (2007) NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis. J Virol 81: 13335–13345. 33. Do Valle TZ, Billecocq A, Guillemot L, Alberts R, Gommet C, et al. (2010) A new mouse model reveals a critical role for host innate immunity in resistance to Rift Valley fever. J Immunol 185: 6146–6156. 34. Mollereau B, Deckert M, Deas O, Rieux-Laucat F, Hirsch F, et al. (1996) CD2- induced apoptosis in activated human peripheral T cells: a Fas-independent pathway that requires early protein tyrosine phosphorylation. J Immunol 156: 3184–3190. 35. Afford SC, Ahmed-Choudhury J, Randhawa S, Russell C, Youster J, et al. (2001) CD40 activation-induced, Fas-dependent apoptosis and NF-kappaB/ AP-1 signaling in human intrahepatic biliary epithelial cells. Faseb J 15: 2345–2354. 36. Wu MY, Liang YR, Wu XY, Zhuang CX (2002) Relationship between Egr-1 gene expression and apoptosis in esophageal carcinoma and precancerous lesions. World J Gastroenterol 8: 971–975. 37. Li J, Billiar TR (1999) Nitric Oxide. IV. Determinants of nitric oxide protection and toxicity in liver. Am J Physiol 276: G1069–1073. 38. Zhao Y, Rangnekar VM (2008) Apoptosis and tumor resistance conferred by Par-4. Cancer Biol Ther 7: 1867–1874. 39. Hung JH, Lu YS, Wang YC, Ma YH, Wang DS, et al. (2008) FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling. Cancer Res 68: 1204–1212. 40. Kiebala M, Polesskaya O, Yao Z, Perry SW, Maggirwar SB (2010) Nuclear factor-kappa B family member RelB inhibits human immunodeficiency virus-1 Tat-induced tumor necrosis factor-alpha production. PLoS One 5: e11875. 41. Matsui H, Hikichi Y, Tsuji I, Yamada T, Shintani Y (2002) LIGHT, a member of the tumor necrosis factor ligand superfamily, prevents tumor necrosis factor- alpha-mediated human primary hepatocyte apoptosis, but not Fas-mediated apoptosis. J Biol Chem 277: 50054–50061. 42. Bustelo XR (2001) Vav proteins, adaptors and cell signaling. Oncogene 20: 6372–6381. 43. Cho SJ, Kang MJ, Homer RJ, Kang HR, Zhang X, et al. (2006) Role of early growth response-1 (Egr-1) in interleukin-13-induced inflammation and remodeling. J Biol Chem 281: 8161–8168. 44. Lomonosova E, Chinnadurai G (2008) BH3-only proteins in apoptosis and beyond: an overview. Oncogene 27 Suppl 1: S2–19. 45. Kong M, Fox CJ, Mu J, Solt L, Xu A, et al. (2004) The PP2A-associated protein alpha4 is an essential inhibitor of apoptosis. Science 306: 695–698. Protective Anti-RVFV NP Responses in Mice 46. Kittipatarin C, Khaled AR (2007) Interlinking interleukin-7. Cytokine 39: 75–83. 47. Jackson LN, Larson SD, Silva SR, Rychahou PG, Chen LA, et al. (2008) PI3K/Akt activation is critical for early hepatic regeneration after partial hepatectomy. Am J Physiol Gastrointest Liver Physiol 294: G1401–1410. 48. Yu-Lee LY (2002) Prolactin modulation of immune and inflammatory responses. Recent Prog Horm Res 57: 435–455. 49. Li Y, Zhou Z, Chen C (2008) WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis. Cell Death Differ 15: 1941–1951. 50. Coleman JW (2002) Nitric oxide: a regulator of mast cell activation and mast cell-mediated inflammation. Clin Exp Immunol 129: 4–10. 51. Peters AL, Stunz LL, Bishop GA (2009) CD40 and autoimmunity: the dark side of a great activator. Semin Immunol 21: 293–300. 52. Senaldi G, Varnum BC, Sarmiento U, Starnes C, Lile J, et al. (1999) Novel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL-6 family. Proc Natl Acad Sci U S A 96: 11458–11463. 53. Dalakas E, Newsome PN, Harrison DJ, Plevris JN (2005) Hematopoietic stem cell trafficking in liver injury. Faseb J 19: 1225–1231. 54. Curnow SJ, Wloka K, Faint JM, Amft N, Cheung CM, et al. (2004) Topical glucocorticoid therapy directly induces up-regulation of functional CXCR4 on primed T lymphocytes in the aqueous humor of patients with uveitis. J Immunol 172: 7154–7161. 55. Lee CG, Hartl D, Matsuura H, Dunlop FM, Scotney PD, et al. (2008) Endogenous IL-11 signaling is essential in Th2- and IL-13-induced inflammation and mucus production. Am J Respir Cell Mol Biol 39: 739–746. 56. Zhou L, Nazarian AA, Smale ST (2004) Interleukin-10 inhibits interleukin-12 p40 gene transcription by targeting a late event in the activation pathway. Mol Cell Biol 24: 2385–2396. 57. Guo CJ, Atochina-Vasserman EN, Abramova E, Foley JP, Zaman A, et al. (2008) S-nitrosylation of surfactant protein-D controls inflammatory function. PLoS Biol 6: e266. 58. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, et al. (2002) Osteopontin–a molecule for all seasons. Qjm 95: 3–13. 59. Denhardt DT, Noda M, O’Regan AW, Pavlin D, Berman JS (2001) Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 107: 1055–1061. 60. Gartel AL, Radhakrishnan SK (2005) Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 65: 3980–3985. 61. Lowenstein CJ, Padalko E (2004) iNOS (NOS2) at a glance. J Cell Sci 117: 2865–2867. 62. Norsworthy PJ, Fossati-Jimack L, Cortes-Hernandez J, Taylor PR, Bygrave AE, et al. (2004) Murine CD93 (C1qRp) contributes to the removal of apoptotic cells in vivo but is not required for C1q-mediated enhancement of phagocytosis. J Immunol 172: 3406–3414. 63. Miletic AV, Graham DB, Sakata-Sogawa K, Hiroshima M, Hamann MJ, et al. (2009) Vav links the T cell antigen receptor to the actin cytoskeleton and T cell activation independently of intrinsic Guanine nucleotide exchange activity. PLoS One 4: e6599. 64. Li J, Nishizawa K, An W, Hussey RE, Lialios FE, et al. (1998) A cdc15-like adaptor protein (CD2BP1) interacts with the CD2 cytoplasmic domain and regulates CD2-triggered adhesion. Embo J 17: 7320–7336. 65. Kunisaki Y, Tanaka Y, Sanui T, Inayoshi A, Noda M, et al. (2006) DOCK2 is required in T cell precursors for development of Valpha14 NK T cells. J Immunol 176: 4640–4645. 66. Zhu R, Diem S, Araujo LM, Aumeunier A, Denizeau J, et al. (2007) The Pro- Th1 cytokine IL-12 enhances IL-4 production by invariant NKT cells: relevance for T cell-mediated hepatitis. J Immunol 178: 5435–5442. 67. Qiao G, Lei M, Li Z, Sun Y, Minto A, et al. (2007) Negative regulation of CD40-mediated B cell responses by E3 ubiquitin ligase Casitas-B-lineage lymphoma protein-B. J Immunol 179: 4473–4479. 68. Qiao G, Li Z, Molinero L, Alegre ML, Ying H, et al. (2008) T-cell receptor- induced NF-kappaB activation is negatively regulated by E3 ubiquitin ligase Cbl-b. Mol Cell Biol 28: 2470–2480. 69. Duttagupta PA, Boesteanu AC, Katsikis PD (2009) Costimulation signals for memory CD8+ T cells during viral infections. Crit Rev Immunol 29: 469–486. 70. Boesteanu AC, Katsikis PD (2009) Memory T cells need CD28 costimulation to remember. Semin Immunol 21: 69–77. 71. Ceredig R, Rauch M, Balciunaite G, Rolink AG (2006) Increasing Flt3L availability alters composition of a novel bone marrow lymphoid progenitor compartment. Blood 108: 1216–1222. 72. Kasler HG, Verdin E (2007) Histone deacetylase 7 functions as a key regulator of genes involved in both positive and negative selection of thymocytes. Mol Cell Biol 27: 5184–5200. 73. Couper KN, Blount DG, Riley EM (2008) IL-10: the master regulator of immunity to infection. J Immunol 180: 5771–5777. 74. Khan WN (2009) B cell receptor and BAFF receptor signaling regulation of B cell homeostasis. J Immunol 183: 3561–3567. 75. Durand CA, Hartvigsen K, Fogelstrand L, Kim S, Iritani S, et al. (2009) Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J Immunol 183: 5673–5684. PLoS ONE | www.plosone.org 12 September 2011 | Volume 6 | Issue 9 | e25027